MedTrace Logo

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

NCT00647764 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-05-17

No results posted yet for this study

Summary

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Conditions

  • Solid Tumor Malignancy
  • Lymphoid Malignancy (Lymphoma and CLL)
  • Leukemia
  • Lymphoma

Interventions

DRUG

SNX-5422 Mesylate Hsp90 inhibitor

dose escalated, tablets twice a week; undetermined duration until disease progression

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Esanex Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00647764 on ClinicalTrials.gov